Investment Rating - The investment rating for the company is "Buy" with a previous rating of "Buy" as well [2] Core Views - The report highlights significant performance improvement for the company, driven by the rising demand in the refrigerant industry and optimized layout in the fluorochemical sector, leading to expected growth in earnings [6][10] Summary by Relevant Sections Financial Performance - In 2024, the company achieved a revenue of RMB 24.46 billion, representing a year-on-year increase of 18.43%, and a net profit attributable to shareholders of RMB 1.96 billion, up 107.69% year-on-year [6][11] - For Q4 2024, the company reported revenue of RMB 6.56 billion, a 41.21% increase year-on-year, and a net profit of RMB 701.97 million, reflecting a 256.83% year-on-year growth [12] - In Q1 2025, the company recorded revenue of RMB 5.80 billion, a 6.05% increase year-on-year, and a net profit of RMB 808.79 million, up 160.64% year-on-year [13] Industry Outlook - The refrigerant industry is experiencing a continuous increase in prices, with the average price of refrigerants rising by 32.69% year-on-year in 2024 [10] - The company holds a leading position in production quotas for refrigerants, with a 26.10% share of the national R22 production quota and a 39.6% share of HFCs production quotas [10] Earnings Forecast - The report projects net profits for 2025, 2026, and 2027 to be RMB 4.18 billion, RMB 5.07 billion, and RMB 5.81 billion respectively, with corresponding earnings per share of RMB 1.55, RMB 1.88, and RMB 2.15 [8][17]
巨化股份(600160):业绩大幅提升,制冷剂价格持续上涨